Production of Stable Cell Lines on the Basis of the Cultured RPMI 8866 B-Cells with Constant and Inducible Expression of the Human Immunodeficiency Virus Tat Protein


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Highly-efficient antiretroviral therapy allows controlling human immunodeficiency virus (HIV) and preventing the development of immunodeficiency. However, the patients who receive therapy may develop different complications, including B-cell lymphomas. One of oncogenesis’ mechanisms in HIV-infected patients is associated with the activity of the viral Tat protein, which is able to penetrate into B-cells. In order to study the effect of the Tat protein on B-cells, a report is given on the production and characterization of the cell lines based on the cultured RPMI 8866 B-cell line demonstrating constant and inducible expression of the Tat protein.

作者简介

M. Gorbacheva

Koltsov Institute of Developmental Biology, Russian Academy of Sciences

Email: musinova@genebee.msu.ru
俄罗斯联邦, Moscow, 119334

M. Tikhomirova

Belozersky Institute of Physicochemical Biology, Moscow State University

Email: musinova@genebee.msu.ru
俄罗斯联邦, Moscow, 119992

D. Potashnikova

Biological Faculty, Moscow State University; Atherothrombosis Laboratory, Evdokimov Moscow State University of Medicine and Dentistry

Email: musinova@genebee.msu.ru
俄罗斯联邦, Moscow, 119992; Moscow, 109240

B. Akbay

UMR 8126, Université Paris-Sud Paris-Saclay, CNRS, Institut Gustave Roussy

Email: musinova@genebee.msu.ru
法国, Villejuif

E. Sheval

Belozersky Institute of Physicochemical Biology, Moscow State University; Biological Faculty, Moscow State University

Email: musinova@genebee.msu.ru
俄罗斯联邦, Moscow, 119992; Moscow, 119992

Y. Musinova

Koltsov Institute of Developmental Biology, Russian Academy of Sciences; Belozersky Institute of Physicochemical Biology, Moscow State University

编辑信件的主要联系方式.
Email: musinova@genebee.msu.ru
俄罗斯联邦, Moscow, 119334; Moscow, 119992

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Inc., 2019